WP
BBIO icon

Woodline Partners’s BridgeBio Pharma BBIO Stock Holding History

Woodline Partners’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.4M Buy
301,312
+300
+0.1% +$21K 0.07% 341
2026
Q1 		$22.4M Buy
301,012
+100
+0% +$7.25K 0.08% 316
2025
Q4 		$23M Buy
300,912
+102,594
+52% +$6.73M 0.09% 284
2025
Q3 		$10.3M Sell
198,318
-1,506,482
-88% -$73.5M 0.05% 435
2025
Q2 		$73.6M Buy
1,704,800
+79,045
+5% +$2.87M 0.39% 47
2025
Q1 		$56.2M Sell
1,625,755
-585,766
-26% -$19.8M 0.37% 71
2024
Q4 		$60.7M Buy
2,211,521
+1,261,772
+133% +$32.6M 0.41% 55
2024
Q3 		$24.2M Buy
949,749
+179
+0% +$4.7K 0.2% 167
2024
Q2 		$24.1M Buy
949,570
+248,821
+36% +$6.8M 0.23% 140
2024
Q1 		$21.7M Buy
700,749
+410,749
+142% +$14M 0.2% 159
2023
Q4 		$11.7M Sell
290,000
-835,634
-74% -$25.1M 0.13% 211
2023
Q3 		$29.7M Buy
1,125,634
+835,634
+288% +$23.7M 0.35% 75
2023
Q2 		$4.99M Sell
290,000
-23,195
-7% -$349K 0.06% 290
2023
Q1 		$5.19M Buy
313,195
+216,896
+225% +$2.53M 0.07% 290
2022
Q4 		$734K Buy
+96,299
New +$922K 0.01% 565

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Woodline Partners's BBIO Position: Q2 2026 in Review

Woodline Partners increased its BridgeBio Pharma (BBIO) stake by 0.1% in Q2 2026, buying an estimated $21K and bringing the position to 301,312 shares worth $22.4M. The position accounts for 0.07% of the portfolio, ranked #341.

Woodline Partners first reported a position in BBIO in Q4 2022 and has held it in 15 quarters since. The position peaked at $73.6M in Q2 2025. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Woodline Partners held 301,312 shares of BridgeBio Pharma worth $22.4M as of Q2 2026.
  • Woodline Partners bought 300 BridgeBio Pharma shares in Q2 2026, an estimated $21K.
  • BridgeBio Pharma made up 0.07% of Woodline Partners's portfolio in Q2 2026, its #341 holding.
  • Woodline Partners first reported a position in BridgeBio Pharma in Q4 2022 and has held it in 15 quarters since.
  • Woodline Partners's BridgeBio Pharma position peaked at $73.6M in Q2 2025.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.